Our product pipeline currently has four programs that have been developed using our proprietary technology. Three of which are approaching Clinical Candidate status, while the fourth is near the Lead Optimization stage.
| Program | Lead Identification | Lead Optimization | Preclinical Development |
|---|---|---|---|
| NUC-1010 LTP-enabled Nucleotide Analog for Hepatitis B |
Lead Identification Phase complete
|
Lead Optimization Phase complete
|
Preclinical Development Phase in progress
|
| NUC-2020 LTP-enabled Agent for Hepatocellular Carcinoma |
Lead Identification Phase complete
|
Lead Optimization Phase in progress
|
Preclinical Development Phase not started
|
| NUC-3030 LTP-enabled Agent for Solid Tumor |
Lead Identification Phase complete
|
Lead Optimization Phase in progress
|
Preclinical Development Phase not started
|
